Arcellx, Inc. (NASDAQ: ACLX) is a biotechnology company focused on developing innovative cancer therapies. Recently, H.C. Wainwright downgraded Arcellx from a Buy to a Neutral rating when the stock was priced at $113.85. This downgrade comes amidst significant developments for the company, including a major acquisition announcement.
Arcellx's stock surged approximately 80% in premarket trading following the news that Gilead Sciences plans to acquire the company in an all-cash deal valued at $7.8 billion. This acquisition is Gilead's largest since 2020, highlighting its strategy to bolster its cancer treatment portfolio. The stock's current price of $113.81 reflects a 77.52% increase, with a $49.70 change.
The acquisition agreement with Gilead Sciences has significantly impacted Arcellx's market performance. The stock has fluctuated between $113.80 and $114.26 today, marking its highest price over the past year. Previously, the lowest price for ACLX in the past year was $47.86, indicating substantial growth.
Arcellx's market capitalization now stands at approximately $6.58 billion, with a trading volume of around 18.59 million shares. This acquisition underscores Gilead's commitment to expanding its biotech sector presence, as highlighted by the Wall Street Journal. The deal involves acquiring the remaining shares of Arcellx, further solidifying Gilead's position in the industry.
